Quince Therapeutics, Inc.
QNCX
$30.32
$0.822.76%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 73.32% | -16.51% | -14.41% | -1.31% | -5.27% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 46.56% | 20.22% | 39.42% | 38.86% | 40.85% |
| Operating Income | -46.56% | -20.22% | -39.42% | -38.86% | -40.85% |
| Income Before Tax | -93.56% | 41.91% | -42.34% | -7.10% | 7.75% |
| Income Tax Expenses | -1,714.93% | -2,208.74% | 3,594.25% | -42.75% | 13.56% |
| Earnings from Continuing Operations | -88.61% | 45.58% | -47.78% | -6.97% | 7.71% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -88.61% | 45.58% | -47.78% | -6.97% | 7.71% |
| EBIT | -46.56% | -20.22% | -39.42% | -38.86% | -40.85% |
| EBITDA | -46.79% | -20.39% | -39.75% | -40.58% | -42.15% |
| EPS Basic | 42.81% | 34.87% | -25.04% | 2.13% | 13.38% |
| Normalized Basic EPS | 44.55% | 1.23% | -78.07% | -57.13% | -61.07% |
| EPS Diluted | 42.81% | 34.87% | -25.04% | 2.13% | 13.38% |
| Normalized Diluted EPS | 44.55% | 1.23% | -78.07% | -57.13% | -61.07% |
| Average Basic Shares Outstanding | 704.19% | 42.57% | 15.72% | 10.54% | 8.72% |
| Average Diluted Shares Outstanding | 704.19% | 42.57% | 15.72% | 10.54% | 8.72% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |